Clinical guideline
Hodgkin lymphoma: EHA Clinical Practice Guidelines for diagnosis, treatment, and follow-up.
Hemasphere · 2026
Studies and guidelines: Lymphoma
32 items with a structured summary · Lymphoma: the complete guide
Clinical guideline
Large B-cell lymphoma (LBCL): EHA Clinical Practice Guidelines for diagnosis, treatment, and follow-up.
Hemasphere · 2025
Clinical guideline
Marginal zone lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Annals of Oncology · 2020
Clinical guideline
Role of Imaging in the Staging and Response Assessment of Lymphoma: Consensus of the International Conference on Malignant Lymphomas Imaging Working Group
JCO · 2014
Clinical trial · Phase 3
Addition of autologous stem-cell transplantation to an ibrutinib-containing first-line treatment in patients aged 18-65 years with mantle cell lymphoma (TRIANGLE): 4·5-year follow-up of a three-arm, randomised, open-label, phase 3 superiority trial of the European MCL Network
Lancet · 2026
82% vs 81%4-year FFS: A+I vs I
Clinical trial · Phase 3
Glofitamab plus gemcitabine and oxaliplatin for relapsed/refractory DLBCL: 3-year follow-up of STARGLO.
Blood Adv · 2026
25.5 vs 12.5 monthsMedian overall survival
Clinical trial · Phase 3
Five-Year Outcomes of the POLARIX Study Comparing Pola-R-CHP and R-CHOP in Patients With Diffuse Large B-Cell Lymphoma
J Clin Oncol · 2025
64.9% vs 59.1%Five-year PFS
Clinical trial · Phase 3
Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial
Lancet · 2024
42% vs 59%Treatment-related morbidity
Clinical trial
Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma.
N Engl J Med · 2022
80.6 months vs 52.9 monthsMedian progression-free survival
Clinical trial · Phase 3
Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial
The Lancet · 2019
96% (95% CI 94 to 99)3-year progression-free survival (four cycles of R-CHOP plus two doses of rituximab)
Clinical trial
Sustained Progression-Free Survival Benefit of Rituximab Maintenance in Patients With Follicular Lymphoma: Long-Term Results of the PRIMA Study.
J Clin Oncol · 2019
10.5 years vs 4.1 yearsMedian progression-free survival
Clinical trial
Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin’s Lymphoma
N Engl J Med · 2016
937 of 1119 patients (83.7%)Negative interim PET-CT
Clinical trial · Phase 3
Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study.
Lancet · 2016
14.6 months vs 6.2 monthsMedian progression-free survival
Clinical trial
Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12
J Clin Oncol · 2014
45.2% vs 44.0%Response rate after two cycles
Clinical trial · Phase 3
Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial
The Lancet Oncology · 2014
46% (95% CI 39–53) vs 88% (83–92)Patients not needing treatment at 3 years: watch and wait vs maintenance rituximab
Clinical trial · Phase 3
Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial.
Lancet · 2013
69.5 months vs 31.2 monthsMedian progression-free survival
Clinical trial · Phase 2
Rituximab plus gemcitabine and oxaliplatin in patients with refractory/relapsed diffuse large B-cell lymphoma who are not candidates for high-dose therapy. A phase II Lymphoma Study Association trial.
Haematologica · 2013
61%Overall response rate after 4 cycles
Clinical trial · Phase 3
Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin's Lymphoma
N Engl J Med · 2022
HR for death 0.59Overall survival
Clinical trial · Phase 3
Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study
Lancet Oncol · 2021
13.2 months vs 8.3 monthsMedian progression-free survival
Clinical trial
Efficacy and safety of epcoritamab in relapsed or refractory large B-cell lymphoma: 3-year update from the EPCORE NHL-1 trial.
Ann Hematol · 2026
59% / 41%Overall response rate / complete response
Clinical trial · Phase 3
Lisocabtagene Maraleucel Versus Standard of Care for Second-Line Relapsed/Refractory Large B-Cell Lymphoma: 3-Year Follow-Up From the Randomized, Phase III TRANSFORM Study
J Clin Oncol · 2025
29.5 months vs 2.4 monthsMedian event-free survival
Clinical trial
Long-term 3-year follow-up of mosunetuzumab in relapsed or refractory follicular lymphoma after ≥2 prior therapies.
Blood · 2025
60.0%Complete response rate
Clinical trial · Phase 3
Obinutuzumab Versus Rituximab Immunochemotherapy in Previously Untreated iNHL: Final Results From the GALLIUM Study
Hemasphere · 2023
63.4% vs 55.7%7-year progression-free survival
Clinical trial
Three-Year Follow-Up of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 Study.
J Clin Oncol · 2023
91%Objective response rate
Clinical trial · Phase 2
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
N Engl J Med · 2017
110 of 111 patients (99%)Successful axi-cel manufacture
Clinical trial · Phase 3
Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial
The Lancet · 2024
Glofit-GemOx: not estimable (NE; 95% CI 13.8 months to NE) vs R-GemOx: 9.0 months (7.3 to 14.4)Median overall survival — primary analysis (median follow-up 11.3 months)
Clinical trial · Phase 3
Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network
Lancet · 2024
88% vs 72%3-year FFS: A+I vs A
Clinical trial
Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell-Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial
J Clin Oncol · 2023
63.1%Overall response rate
Clinical trial · Phase 3
Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial
Lancet · 2022
10.1 vs 2.3 monthsMedian event-free survival
Clinical trial · Phase 2
Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study
The Lancet Oncology · 2022
54 patients (60.0%; 95% CI 49.1–70.2)Complete response (IRC-assessed)
Clinical trial · Phase 2
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
N Engl J Med · 2020
93%Objective response (primary efficacy analysis, 60 patients)
Clinical trial · Phase 3
Obinutuzumab for the First-Line Treatment of Follicular Lymphoma
N Engl J Med · 2017
80.0% vs 73.3% (obinutuzumab vs rituximab)3-year progression-free survival (estimated)
Nothing found.